Mononucleosis and Epstein–Barr virus infection: treatment and medication

References

• Johannsen EC, Kaye KM. Epstein-Barr Virus (Infectious Mononucleosis). In: Mandell GL, Douglas RG, Bennett JE, editors. Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, PA: Elsevier Churchill Livingston; 2010:1989–2010.
   Google Scholar
• Andersson JP Clinical aspects of Epstein-Barr virus infection. Scand JInfect Dis Suppl. 1991;80:94–104.
   Google Scholar
• Henle G, Henle W, Clifford P, et al. Antibodies to Epstein-Barr virus in Burkitt’s lymphoma and control groups. J Nat Cancer Inst. 1969;43(5):1147–1157.
   Google Scholar
• Luzuriaga K, Sullivan JL. Infectious mononucleosis. N Engl J Med. 2010;362(21):1993–2000.
   PubMed Web of Science ®Google Scholar
• Naher H, Gissmann L, Freese UK, Petzoldt D, Helfrich S. Subclinical Epstein-Barr virus infection of both the male and female genital tract-indication for sexual transmission. J Invest Dermatol. 1992;98(5):791–793.
   Web of Science ®Google Scholar
• Crawford DH, Macsween KF, Higgins CD, et al. A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. Clin Infect Dis. 2006;43(3):276–282.
   PubMed Web of Science ®Google Scholar
• Higgins CD, Swerdlow AJ, Macsween KF, et al. A study of risk factors for acquisition of Epstein-Barr virus and its subtypes. J Infect Dis. 2007;195(4):474–482.
   Web of Science ®Google Scholar
• Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol. 2001;1(1):75–82.
   PubMed Web of Science ®Google Scholar
• Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med. 2004;350(13):1328–1337.
   PubMed Web of Science ®Google Scholar
• Chen MR. Epstein-Barr virus, the immune system, and associated diseases. Front Microbiol. 2011;2:5.
   PubMed Web of Science ®Google Scholar
• Souza TA, Stollar BD, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. Peripheral B cells latently infected with Epstein-Barr virus display molecular hallmarks of classical antigen-selected memory B cells. Proc Natl Acad Sci U S A. 2005;102(50):18093–18098.
   Web of Science ®Google Scholar
• Hoagland RJ. Infectious mononucleosis. Prim Care. 1975;2(2):295–307.
   Google Scholar
• Macsween KF, Higgins CD, McAulay KA, et al. Infectious mononucleosis in university students in the United Kingdom: evaluation of the clinical features and consequences of the disease. Clin Infect Dis. 2010;50(5):699–706.
   PubMed Web of Science ®Google Scholar
• Ebell MH. Epstein-Barr virus infectious mononucleosis. Am Fam Physician. 2004;70(7):1279–1287.
   PubMed Web of Science ®Google Scholar
• Junker AK. Epstein-Barr virus. Pediatr Rev. 2005;26(3):79–85.
   Web of Science ®Google Scholar
• Bisno AL, Gerber MA, Gwaltney JM Jr, Kaplan EL, Schwartz RH. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Clin Infect Dis. 2002;35(2):113–125.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention, National Center for Infectious Diseases. Epstein-Barr virus and infectious mononucleosis. Updated May 16, 2006. Available from: http://www.cdc.gov/ncidod/ diseases/ebv.htm. Accessed December 20, 2011.
   Google Scholar
• Linderholm M, Boman J, Juto P, Linde A. Comparative evaluation of nine kits for rapid diagnosis of infectious mononucleosis and Epstein-Barr virus-specific serology. J Clin Microbiol. 1994;32(1):259–261.
   PubMed Web of Science ®Google Scholar
• Bruu AL, Hjetland R, Holter E, et al. Evaluation of 12 commercially available tests for detection of Epstein-Barr Virus-specific and heterophile antibodies. Clin Diagn Lab Immunol. 2000;7(3):451^56.
   Google Scholar
• de Ory F, Guisasola ME, Sanz JC, García-Bermejo I. Evaluation of four commercial systems for the diagnosis of Epstein-Barr virus primary infections. Clin Vaccine Immunol. 2011;18(3):444–448.
   Google Scholar
• Pitetti RD, Laus S, Wadowsky RM. Clinical evaluation of a quantitative real time polymerase chain reaction assay for diagnosis of primary Epstein-Barr virus infection in children. Pediatr Infect Dis J. 2003;22(8):736–739.
   Web of Science ®Google Scholar
• Odumade OA, Hogquist KA, Balfour HH Jr. Progress and problems in understanding and managing primary Epstein-Barr virus infections. Clin Microbiol Rev. 2011;24(1):193–209.
   PubMed Web of Science ®Google Scholar
• Putukian M, O’Connor FG, Stricker P, et al. Mononucleosis and athletic participation: an evidence-based subject review. Clin J Sport Med. 2008;18(4):309–315.
   PubMed Web of Science ®Google Scholar
• Torre D, Tambini R. Acyclovir for treatment of infectious mononucleosis: a meta-analysis. Scand J Infect Dis. 1999;31(6):543–547.
   PubMed Web of Science ®Google Scholar
• Balfour HH Jr, Hokanson KM, Schacherer RM, et al. A virologic pilot study of valacyclovir in infectious mononucleosis. J Clin Virol. 2007;39(1):16–21.
   PubMed Web of Science ®Google Scholar
• Miller CS, Avdiushko SA, Kryscio RJ, Danaher RJ, Jacob RJ. Effect of prophylactic valacyclovir on the presence of human herpesvirus DNA in saliva of healthy individuals after dental treatment. J Clin Microbiol. 2005;43(5):2173–2180.
   Web of Science ®Google Scholar
• Hoshino Y, Katano H, Zou P, et al. Long-term administration of valacyclovir reduces the number of Epstein-Barr virus (EBV)-infected B cells but not the number of EBV DNA copies per B cell in healthy volunteers. J Virol 2009;83(22):11857–11861.
   PubMed Web of Science ®Google Scholar
• Williams-Aziz SL, Hartline CB, Harden EA, et al. Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob Agents Chemother. 2005;49(9):3724–3733.
   PubMed Web of Science ®Google Scholar
• Candy B, Hotopf M. Steroids for symptom control in infectious mononucleosis. Cochrane Database Syst Rev. 2006;3:CD004402.
   Google Scholar
• Sokal EM, Hoppenbrouwers K, Vandermeulen C, et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immuno- genicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis. 2007;196(12):1749–1753.
   PubMed Web of Science ®Google Scholar
• Cohen JI, Fauci AS, Varmus H, Nabel GJ. Epstein-Barr virus: an important vaccine target for cancer prevention. Sci Transí Med. 2011;3(107):107fs7.
   Web of Science ®Google Scholar
• Williams H, Crawford DH. Epstein-Barr virus: the impact of scientific advances on clinical practice. Blood. 2006;107(3):862–869.
   PubMed Web of Science ®Google Scholar
• Rezk SA, Weiss LM. Epstein-Barr virus-associated lymphoproliferative disorders. Hum Pathol. 2007;38(9):1293–1304.
   PubMed Web of Science ®Google Scholar
• Dolcetti R, Guidoboni M, Gloghini A, Carbone A. EBV-associated tumors: pathogenetic insights for improved disease monitoring and treatment. Curr Cancer Ther Rev. 2005;1:27–44.
   Google Scholar
• Macsween KF, Crawford DH. Epstein-Barr virus-recent advances. Lancet Infect Dis. 2003;3(3):131–140.
   PubMed Web of Science ®Google Scholar
• Handel AE, Williamson AJ, Disanto G, Handunnetthi L, Giovannoni G, Ramagopalan SV An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLoS One. 2010;5(9):pii:e12496.
   Web of Science ®Google Scholar
• Toussirot E, Roudier J. Epstein-Barr virus in autoimmune diseases. Best PractRes Clin Rheumatol. 2008;22(5):883–896.
   PubMed Web of Science ®Google Scholar
• Jenson HB. Acute complications of Epstein-Barr virus infectious mononucleosis. Curr Opin Pediatr. 2000;12(3):263–268.
   Web of Science ®Google Scholar
• Lazarus KH, Baehner RL. Aplastic anemia complicating infectious mononucleosis: a case report and review of the literature. Pediatrics. 1981;67(6):907–910.
   Web of Science ®Google Scholar
• Steeper TA, Horwitz CA, Moore SB, et al. Severe thrombocytopenia in Epstein-Barr virus-induced mononucleosis. West JMed. 1989;150(2):170–173.
   Google Scholar
• Hammond WP, Harlan JM, Steinberg SE. Severe neutropenia in infectious mononucleosis. West J Med. 1979;131(2):92–97.
   Google Scholar
• Maakaroun NR, Moanna A, Jacob JT, Albrecht H. Viral infections associated with haemophagocytic syndrome. Rev Med Virol. 2010;20(2):93–105.
   PubMed Web of Science ®Google Scholar
• Mroczek EC, Weisenburger DD, Grierson HL, Markin R, Purtilo DT. Fatal infectious mononucleosis and virus-associated hemophagocytic syndrome. Arch Pathol Lab Med. 1987;111(6):530–535.
   Web of Science ®Google Scholar
• Wohl DL, Isaacson JE. Airway obstruction in children with infectious mononucleosis. Ear Nose Throat J. 1995;74(9):630–638.
   Google Scholar
• Sherlock S, Dooley J. Disease of the Liver and Billiary System. 9th ed. Oxford, UK: Blackwell Scientific Publications; 1993:288–290.
   Google Scholar
• Kofteridis DP, Koulentaki M, Valachis A, et al. Epstein Barr virus hepatitis. Eur J Intern Med. 2011;22(1):73–76.
   Web of Science ®Google Scholar
• Farley DR, Zietlow SP, Bannon MP, Farnell MB. Spontaneous rupture of the spleen due to infectious mononucleosis. Mayo Clin Proc. 1992;67(9):846–853.
   PubMed Web of Science ®Google Scholar
• bestpractice.bmj.com. BMJ Publishing Group Limited 2011. Available from: http://bestpractice.bmj.com/best-practice/monograph/123/ follow-up.html. Accessed December 20, 2011.
   Google Scholar
• Candy B, Chalder T, Cleare AJ, et al. Recovery from infectious mononucleosis: a case for more than symptomatic therapy? A systematic review. Br J Gen Pract. 2002;52(483):844–851.
   PubMed Web of Science ®Google Scholar
• Whiting P, Bagnall AM, Sowden AJ, et al. Interventions for the treatment and management of chronic fatigue syndrome: a systematic review. JAMA. 2001;286(11):1360–1368.
   PubMed Web of Science ®Google Scholar